DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Morbidity and mortality for critically ill patients with infections remains a global healthcare problem. We aimed to determine whether β-lactam antibiotic dosing in critically ill patients achieves concentrations associated with maximal activity and whether antibiotic concentrations affect patient outcome. METHODS: This was a prospective, multinational pharmacokinetic point-prevalence study including 8 β-lactam antibiotics. Two blood samples were taken from each patient during a single dosing interval. The primary pharmacokinetic/pharmacodynamic targets were free antibiotic concentrations above the minimum inhibitory concentration (MIC) of the pathogen at both 50% (50% f T>MIC) and 100% (100% f T>MIC) of the dosing interval. We used skewed logistic regression to describe the effect of antibiotic exposure on patient outcome. RESULTS: We included 384 patients (361 evaluable patients) across 68 hospitals. The median age was 61 (interquartile range [IQR], 48-73) years, the median Acute Physiology and Chronic Health Evaluation II score was 18 (IQR, 14-24), and 65% of patients were male. Of the 248 patients treated for infection, 16% did not achieve 50% f T>MIC and these patients were 32% less likely to have a positive clinical outcome (odds ratio [OR], 0.68; P = .009). Positive clinical outcome was associated with increasing 50% f T>MIC and 100% f T>MIC ratios (OR, 1.02 and 1.56, respectively; P < .03), with significant interaction with sickness severity status. CONCLUSIONS: Infected critically ill patients may have adverse outcomes as a result of inadeqaute antibiotic exposure; a paradigm change to more personalized antibiotic dosing may be necessary to improve outcomes for these most seriously ill patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Some observational studies suggested that prompt initiation of appropriate empiric antifungal therapy may be associated with a reduction in mortality, however these studies do not prove a causal relationship between antifungal therapy and outcome, nor do they clarify the role of timing of treatment, and some other studies have failed to show this association (167,(171)(172)(173).”
From Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. (2021) · cites this paper as [171]
In the citing paper
“Antibiotics are subject to changes in PK/PD parameters in sepsis and septic shock where resultant concentrations may be too low risking clinical failure, or too high leading to toxicity (Table 3) [237–239].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [238]
Citations
Cites
APACHE II-A Severity of Disease Classification System: Reply
Knaus, W. A., Draper, E. A., Wagner, D. P., & Zimmerman, J. E. (1986) · Critical Care Medicine · doi:10.1097/00003246-198608000-00028 · Cited by 13,376 · cited 1×
“Various demographic and clinical data were collected including age, sex, height, weight, presence of renal replacement therapy, and measures of organ function and levels of patient sickness severity as described by the APACHE II (Acute Physiology and Chronic Health Evaluation II) score [15] on admission and SOFA (Sequ…”
MethodKumar, A., Roberts, D., Wood, K. E., Light, B., Parrillo, J. E., Sharma, S., Suppes, R., Feinstein, D., Zanotti, S., Taiberg, L., et al. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000217961.75225.e9 · Cited by 6,109
International Study of the Prevalence and Outcomes of Infection in Intensive Care Units
Vincent, J.-L. (2009) · JAMA · doi:10.1001/jama.2009.1754 · Cited by 3,618
Vincent, J.-L., de Mendonca, A., Cantraine, F., Moreno, R., Takala, J., Suter, P. M., Sprung, C. L., Colardyn, F., & Blecher, S. (1998) · Critical Care Medicine · doi:10.1097/00003246-199811000-00016 · Cited by 3,463
Craig, W. A. (1998) · Clinical Infectious Diseases · doi:10.1086/516284 · Cited by 2,908 · cited 1×
“From a pharmacokinetic/pharmacodynamic (PK/PD) perspective, preclinical studies have defined these antibiotics to be time dependent, that is, the time for which the free (unbound) antibiotic concentration is maintained above the minimum inhibitory concentration (MIC) is the determinate factor associated with bacterial…”
BackgroundAntimicrobial pharmacodynamics: critical interactions of 'bug and drug'
Drusano, G. L. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro862 · Cited by 930 · cited 1×
“Whereas animal in vivo studies have defined an f T>MIC between 40% and 70% of the dosing interval as being necessary [11], retrospective clinical evaluations have suggested that larger drug exposures are required, with β-lactam concentrations up to 4 times the MIC for the entire dosing interval being suggested [12, 13…”
BackgroundHarbarth, S., Garbino, J., Pugin, J., Romand, J. A., Lew, D., & Pittet, D. (2003) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.07.005 · Cited by 637
McKinnon, P. S., Paladino, J. A., & Schentag, J. J. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.12.009 · Cited by 464 · cited 2×
“Whereas animal in vivo studies have defined an f T>MIC between 40% and 70% of the dosing interval as being necessary [11], retrospective clinical evaluations have suggested that larger drug exposures are required, with β-lactam concentrations up to 4 times the MIC for the entire dosing interval being suggested [12, 13…”
BackgroundResultSubtherapeutic Initial β-Lactam Concentrations in Select Critically Ill Patients
Udy, A. A., Varghese, J. M., Altukroni, M., Briscoe, S., McWhinney, B. C., Ungerer, J. P., Lipman, J., & Roberts, J. A. (2012) · Chest · doi:10.1378/chest.11-1671 · Cited by 414 · cited 1×
“These patients may have augmented renal clearances needing either higher doses or more frequent dosing to overcome increased drug elimination [22, 23].”
BackgroundSelf-citationAntibiotics in critically ill patients: A systematic review of the pharmacokinetics of β-lactams.
Gonçalves-Pereira, J., & Póvoa, P. (2011) · Critical Care · doi:10.1186/cc10441 · Cited by 408 · cited 2×
“It has been suggested that superior infection outcomes could be achieved in critically ill patients by optimization of the pharmacokinetic exposure of antibiotics [5, 6].”
Background
Cited by
Items 901–1,000 of 1,000
Ren, C., Huang, F., Cheng, V., Xie, J., Roberts, J. A., & Abdul-Aziz, M. H. (2025) · Clinical Pharmacokinetics · doi:10.1007/s40262-025-01596-z · Cited by 1
“Standard dosing regimens are often insufficient, as these patients experience pathophysiological changes that alter drug pharmacokinetics [1–3].”
Self-citationHansel, J., Lain, J., Erhieyovwe, E. O., Ismayilli, A., Orr, J., Keevil, B. G., Ogungbenro, K., Dark, P. M., & Felton, T. (2025) · Journal of the Intensive Care Society · doi:10.1177/17511437251404324 · Cited by 1
Bergmann, F., Prager, M., Pracher, L., Kumpf, K., Zeitlinger, M. A., & Jorda, A. (2026) · Annals of Intensive Care · doi:10.1016/j.aicoj.2025.100022 · Cited by 1
de Hoop‐Sommen, M. A., Freriksen, J. J. M., van der Heijden, J. E. M., Jacobs, J., Oosterlaan, Y., Staring, C. M., van der Zeeuw, S. L., van der Zanden, T. M., van der Bruggen, J.-T. T., Quaak, M. S. W., et al. (2026) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaf463 · Cited by 1
Wilson, R. C., Gilchrist, M. J., Cele, R., d’Arc, S., Mills, E. A., Ndhlovu, C., Balancio, B., Arkell, P., Read, L., Bayliss, M. A. J., et al. (2025) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaf484 · Cited by 1
“Roberts et al . reported considerably wider variation in β -lactam concentrations in critical care patients, 22 however, comparable data outside of this population are unavailable.”
Can Model-Informed Precision Dosing of Beta-Lactams in Critical Care Improve Clinical Outcomes?
Oakley, R. S., Ulldemolins, M., Hernández-Mitre, M. P., Colmenero, M., Roberts, N. A., Roberts, J. A., Lipman, J., & Heffernan, A. J. (2026) · Chemotherapy · doi:10.1159/000550822 · Cited by 1
“Given that beta-lactam antibiotic concentrations may vary up to 500-fold between critically ill patients, it is highly likely that patients may experience either subtherapeutic or potentially toxic exposures [5].”
InfluentialSelf-citationSetiawan, E., Gonzalez, A., Wölky, S. A., Cotta, M. O., Liu, X., Sosilya, H., Maresco-Pennisi, D. L., Novy, E., Ordoñez, J., Lukas, D. L., et al. (2026) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2026.107817 · Cited by 1
Self-citationManagement of severe infections by multi-resistant Gram-negative bacteria in critically ill patients
Garnacho‐Montero, J., Adriaensens-Pérez, M., Aldabó-Pallás, T., Anaya-Carrión, N., Andaluz‐Ojeda, D., Cantón‐Bulnes, M. L., PASCALE, G. D., Fernández-Delgado, E., Póvoa, P. M. S. R., Galleymore, P. R., et al. (2026) · Medicina Intensiva (English Edition) · doi:10.1016/j.medine.2026.502443 · Cited by 1
Závorszky, L., Szabó, B. G., Holub, L., Tarr, P., Galgóczi, J., Erőss, A., Péter, Á., Kӓfer, M., Biró, Z., Karvaly, G., et al. (2026) · Burns · doi:10.1016/j.burns.2026.108138 · Cited by 1
Mattisson, Y., & Tverring, J. (2026) · Journal of International Medical Research · doi:10.1177/03000605261457800 · Cited by 1
Leiwolf, M., Grégoire, N., Magréault, S., Franck, B., Krekounian, O., Woillard, J., & Aranzana‐Climent, V. (2026) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70296 · Cited by 1
Williams, P. G., Cotta, M. O., Wilks, K. M., Farkas, A., Spelman, T., & Roberts, J. A. (2026) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkag234 · Cited by 1
“3,4 A key objective of antibiotic dosing is to achieve pre-defined PK/pharmacodynamic (PD) targets associated with therapeutic success.”
Self-citationNeves, D. V., Villani, U., DʼAgate, S., Oosterholt, S. P., Cavalli, R. D. C., Carmona, F., Lanchote, V. L., & Pasqua, O. E. D. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70709 · Cited by 1
Time to Antibiotics or Time to Effective Antimicrobial Therapy?
Kumar, T. P., & Gupta, N. R. (2026) · Clinical Infectious Diseases · doi:10.1093/cid/ciag565 · Cited by 1
Who should receive extended infusion beta-lactam therapy?
Roman, C., Solh, T., & Damer, K. M. (2016) · JAAPA · doi:10.1097/01.jaa.0000480576.16121.88 · Cited by 1
Pharmacodynamic Considerations in Critically Ill Patients
Sinnollareddy, M., & Roberts, J. A. (2016) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-3323-5_21 · Cited by 1
Self-citationWhat We Learned From the EU-VAP/CAP Study for Severe Pneumonia
Leoni, D., Blot, S. I., Tsigou, E., & Koulenti, D. (2017) · Clinical Pulmonary Medicine · doi:10.1097/cpm.0000000000000204 · Cited by 1
Self-citationAntibiotic Stewardship in Orthopädie und Unfallchirurgie
Horn, D., Köck, R., Wähnert, D., Roßlenbroich, S. B., & Raschke, M. J. (2017) · OP-Journal · doi:10.1055/s-0043-102343 · Cited by 1
“Eine Reihe von Untersuchungen bei kritisch kranken Patienten hat gezeigt, dass allgemeine Dosierungsschemata auf Grundlage der Zulassungsdaten in vielen Fällen zu Unterdosierung führen [19].”
BackgroundPharmacokinetic and Pharmacodynamic Tools to Increase Efficacy
Sinnollareddy, M., Cotta, M. O., & Roberts, J. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-810477-4.00007-6 · Cited by 1
Self-citationInfectious diseases: the 10 common truths I never believed
Rello, J., Alp, E., & Vandana, K. E. (2018) · Intensive Care Medicine · doi:10.1007/s00134-018-5272-z · Cited by 1
“The DALI study was a multicenter observational study conducted in a network of European intensive care units (ICUs), which demonstrated that many patients exposed to label doses of cephalosporins present suboptimal plasma levels falling below PK/PD targets [13].”
MethodSelf-citationPaul, S. K., Roberts, J. A., Lipman, J., Deans, R., & Samanta, M. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0690-1 · Cited by 1
Self-citationPoda, O. A., Kryuchko, T. O., Несина, И. Н., Tkachenko, O. Y., & Кузьменко, Н. В. (2019) · Wiadomości Lekarskie · doi:10.36740/wlek201905130 · Cited by 1
Ventilator-Associated Pneumonia
Chastre, J. E., & Luyt, C. E. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-3383-5.00034-8 · Cited by 3
Antimicrobial Therapy in Septic Shock Is Conservative During Resuscitation and Maintenance Phases
Hsu, G., Gonzales, J. P., Seung, H., Heavner, M. S., Jean, W., & Shah, N. G. (2020) · Journal of Pharmacy Technology · doi:10.1177/8755122520921516 · Cited by 1
Antimicrobial Stewardship in Intensive Care Unit
Ray, S. S. (2020) · Springer eBooks · doi:10.1007/978-981-15-4039-4_25 · Cited by 1
Kacířová, I., & Grundmann, M. (2020) · Klinická farmakologie a farmacie · doi:10.36290/far.2020.011 · Cited by 1
Liu, X., Fu, Q., Du, X., Zhu, Z., Xu, X., Tang, Y., Hong, G. O. N. G., LiPing, D. U., Li, J., Bin, Z. H. A. O., et al. (2021) · Scientia Sinica Vitae · doi:10.1360/ssv-2021-0180 · Cited by 1
Silva, H. A., Santana, R. S., Capucho, H. C., de Lima, A. P. P., Rocha, C. L. D. A., & Lima, R. F. (2021) · Research Society and Development · doi:10.33448/rsd-v10i14.21691 · Cited by 1
Clinical Impact of Bloodstream Infections – Characterization, Risk factors and Outcome
Holmbom, M. (2021) · Linköping University medical dissertations · doi:10.3384/diss.diva-181406 · Cited by 2
Aregger, F., & Enghard, P. (2021) · Der Nephrologe · doi:10.1007/s11560-021-00553-8 · Cited by 1
“Daher sollte insbesondere bei schweren Infektionen und AKI eine eher höhere Dosierung von Antibiotika, falls möglich mit Spiegelbestimmung, erwogen werden [43].”
Ni, S.-Q., Teng, W.-B., Fu, Y., Su, W., Yang, Z. H., Cai, J., Xu, J.-N., Deng, X., Liu, X., Fu, S.-N., et al. (2022) · Trials · doi:10.1186/s13063-022-06264-2 · Cited by 1
“In DALI research [31], 60% subjects have not reached PD target.”
BackgroundAntimicrobial Use in Surgical Intensive Care
Duncan, R. A. (2016) · Springer eBooks · doi:10.1007/978-3-319-19668-8_33 · Cited by 1
Abbott, I. J., & Cairns, K. A. (2016) · Springer eBooks · doi:10.1007/978-3-319-44034-7_2 · Cited by 1
SASCM guideline for daptomycin use in South Africa – 2017 update
Lowman, W., Coetzee, J., & Perovic, O. (2017) · Southern African Journal of Infectious Diseases · doi:10.4102/sajid.v32i2.58 · Cited by 1
Schatz, L. M., Zöller, M., Scharf, C., & Liebchen, U. (2022) · Die Anaesthesiologie · doi:10.1007/s00101-022-01150-7 · Cited by 1
Therapeutic Drug Monitoring of Antibiotics Is Needed in the Treatment of Sepsis
Плотников, Г. П., Kudryavtsev, A. N., Клеузович, А. А., Chizhov, A., Ponomarev, A. A., Larin, S. S., Литвин, Е. А., & Anastasevich, L. A. (2022) · Messenger of Anesthesiology and Resuscitation · doi:10.21292/2078-5658-2022-19-6-62-71 · Cited by 1
Roux, D., Bénichou, N., Hajage, D., Martin‐Lefèvre, L., de Prost, N., Lerolle, N., Beauport, D. T., Boulet, É., Mayaux, J., Mégarbane, B., et al. (2023) · Annals of Intensive Care · doi:10.1186/s13613-023-01105-0 · Cited by 1
Liu, C., Cojutti, P. G., Giannella, M., Roberto, M., Casadei, B., Cristiano, G., Papayannidis, C., Vianelli, N., Zinzani, P. L., Viale, P., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15031022 · Cited by 1
Antimicrobial use in the critical care patient
Epstein, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-76469-8.00181-7 · Cited by 1
Current Trends in Intensive Therapy of Peritonitis and Abdominal Sepsis
СУХОДОЛЯ, А. І., & Krenov, K. Y. (2023) · Acta Scientific Gastrointestinal Disorders · doi:10.31080/asgis.2023.06.0541 · Cited by 2
Konuma, T., Takano, K., Monna‐Oiwa, M., Isobe, M., Kato, S., Takahashi, S., & Nannya, Y. (2023) · International Journal of Hematology · doi:10.1007/s12185-023-03669-w · Cited by 1
Dilawri, A., Muir, J., Brodie, D., Abrams, D. C., Agerstrand, C. L., Madahar, P., & Dzierba, A. L. (2024) · Journal of Critical Care · doi:10.1016/j.jcrc.2024.154534 · Cited by 1
Hasibeder, W. R., & Kathrein, A. (2024) · Anästhesie Nachrichten · doi:10.1007/s44179-024-00233-7 · Cited by 1
Лакатош, В. П., & Бондаренко, Н. П. (2024) · Bulletin of Problems Biology and Medicine · doi:10.29254/2077-4214-2024-4-175-398-409 · Cited by 1
Matusik, É. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.580163 · Cited by 1
“Regarding inter/intra-individual variability, individualized PK-PD targets and dosing are required (Goldstein and Nolin, 2014; Roberts and Roberts, 2014; Shaw et al., 2016).”
BackgroundFlateau, C., Riazi, A., Cassard, B., Camus, M., & Diamantis, S. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac140 · Cited by 1
Beta-Lactams in Critically Ill Children: Time to Step Up Our Game?*
Thibault, C., Marsot, A., & Autmizguine, J. (2022) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0000000000002982 · Cited by 1
Abdul-Aziz, M. H., Hammond, N. E., Brett, S. J., Cotta, M. O., Waele, J. J. D., Tanna, G. L. D., Dulhunty, J. M., Elkady, H., Eriksson, L., Hasan, M. S., et al. (2023) · medRxiv · doi:10.1101/2023.05.15.23289889 · Cited by 1
“Conventional antibiotic dosing rarely considers these issues and therefore, has a higher likelihood to fail in this patient population (5-7).”
BackgroundSelf-citationEditorial: Infections in the intensive care unit, volume III
Zhu, C., Lin, B., Zhang, Z., & Yu, Y. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1719505 · Cited by 1
Multiresistente gramnegative Erreger
Kern, J. M. (2015) · Springer eBooks · doi:10.1007/978-3-642-54676-1_548-1
Dosierung von Antiinfektiva bei CKD (5D)
Vossen, M. G., Kielstein, J. T., & Thalhammer, F. (2014) · Der Nephrologe · doi:10.1007/s11560-014-0880-2
Abdul-Aziz, M. H. (2016) · The University of Queensland · doi:10.14264/uql.2016.450
“Maintaining effective beta-lactams exposure for extended periods or increasing % fT>MIC would be especially appropriate in immunocompromised patients including critically ill patients [7, 27, 163].”
BackgroundInfluentialInhaled antibiotics in critical care
Luyt, C. E., & Chastre, J. E. (2017) · European Respiratory Society eBooks · doi:10.1183/2312508x.10004716
修, 西., 裕司, 小., 茂亮, 井., 敏明, 射., 均, 今., 江木盛時, 垣花泰之, 成樹, 久., 穣治, 小., 智仁, 貞., et al. (2016) · Journal of the Japanese Society of Intensive Care Medicine · doi:10.3918/jsicm.24s0008
Update in Critical Care Medicine: Evidence Published in 2016
Hepokoski, M., & Malhotra, A. (2017) · Annals of Internal Medicine · doi:10.7326/m17-0138
β-Lactams Dosing in Overweight Critically Ill Patients: Are We Driving in the Dark?*
Aubron, C., & Corallo, C. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002388
Evaluation of Clinical Outcomes With Various Meropenem Dosing Regimens in Septic Patients
Devanathan, A. S., Corkish, M. E., Rohde, K. A., & Campbell-Bright, S. L. (2017) · Infectious Diseases in Clinical Practice · doi:10.1097/ipc.0000000000000548
Improving antibiotic dosing in critically ill Australian Indigenous patients with severe sepsis
Tsai, D. (2017) · The University of Queensland · doi:10.14264/uql.2017.481
The Value and Interpretation of Microbiological Specimens in the Management of cIAI
Lowman, W. (2017) · Hot topics in acute care surgery and trauma · doi:10.1007/978-3-319-59704-1_20
Appropriate Antimicrobial Therapy in Critically Ill Patients
Sime, F. B., & Roberts, J. A. (2017) · Hot topics in acute care surgery and trauma · doi:10.1007/978-3-319-59704-1_21
Self-citationProlonged Infusion of Beta-lactam Antibiotics in Critically Ill Patients: Revisiting the Evidence
Dhaese, S. A. M., Stove, V. V., & Waele, J. J. D. (2018) · Annual update in intensive care and emergency medicine · doi:10.1007/978-3-319-73670-9_5
Ulldemolins, M. (2017) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)
Principles of Antimicrobial Prescription in Intensive Care Unit Patients With Acute Kidney Injury
Wong, A., & Kane‐Gill, S. L. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-44942-7.00092-3
Fournier, A., Eggimann, P., Pantet, O., Pagani, J., Dupuis‐Lozeron, E., Pannatier, A., Sadeghipour, F., Voirol, P., & Que, Y. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01343-18
Mori, N., Kawahara, Y., Tsuchiya, T., Sekine, K., Hara, T., & 高倉, 照. (2018) · JAPANES JOURNAL OF MEDICAL INSTRUMENTATION · doi:10.4286/jjmi.88.538
Scharf, C. (2018) · Elektronische Hochschulschriften der LMU München (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.22990
Lwin, N., Liu, Z., Loewenthal, M. R., Dobson, P. M., Yoo, J. W., Galettis, P., Lai, K., & Martin, J. H. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/499848
Brauns, E., & Gustot, T. (2019) · Wiley eBooks · doi:10.1002/9781119211419.ch26
Medikamentengabe und allgemeine Komplikationen bei extrakorporalen Verfahren
Brinkmann, A., Bürle, M., Frey, O. R., König, C., Richter, D., Röhr, A. C., & Träger, K. (2019) · Elsevier eBooks · doi:10.1016/b978-3-437-22791-2.00002-8
Sumi, C. D. (2020) · The University of Queensland · doi:10.14264/uql.2020.871
Personalised antimicrobial management in secondary care
Rawson, T. M. (2018) · Spiral (Imperial College London) · doi:10.25560/79665
Obstetric and Gynecological Infections
Khanna, P., & Selvam, V. (2020) · Springer eBooks · doi:10.1007/978-981-15-4039-4_9
Udy, A. A. (2014) · The University of Queensland · doi:10.14264/uql.2015.114
Species distribution and antibiotic resistance in Shandong, China: 2010–2016
Jiang, Z., Zhang, Y., Zhu, Y., Zhang, L., Li, C., Jian, X., Yao, Y.-M., Du, B., Xi, X., & Qu, Y.-Q. (2021) · Journal of Emergency and Critical Care Medicine · doi:10.21037/jeccm-20-121
“Unfortunately, 30% to 60% of the antibiotics used in the ICU were suboptimal, inappropriate and unnecessary (4-7).”
BackgroundRationaler Antibiotikaeinsatz in der Gefäßchirurgie
Lanckohr, C. (2021) · Gefässchirurgie · doi:10.1007/s00772-021-00755-3
Tappatá, L. L., Maurizi, D. M., Spadaro, M. L., Fuks, V., Lamot, L., Petasny, M., Martínez, L. S., & Kraemer, P. G. (2019) · Actualizaciones en Sida e Infectología · doi:10.52226/revista.v27i100.16
Märtson, A., & Alffenaar, J. C. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab401
Antibiotic consumption and management at Kocani General Hospital – Annual report
Ilieva, N., Nikolova, M., Pankov, D., Crcarevska, M. S., Mladenovska, K., Shalabalija, D., Mihailova, L., Gigopulu, O., & Dodov, M. G. (2019) · Macedonian Pharmaceutical Bulletin · doi:10.33320/maced.pharm.bull.2019.65.02.002
Meropenem and piperacillin-tazobactam levels for critical care patients during empiric therapy
Hoo, G. S. R., Chua, N. G. S., Ng, T. M., Lee, L., Kwa, A. L., & Ling, L. M. (2021) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.2020472
Fong, G. R., Chahine, E. B., Justo, J. A., Narayanan, N., Heil, E. L., Stover, K. R., Cho, J. C., Jenkins, Z. N., & MacDougall, C. (2021) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.1541
“Course length (weeks) 15 (14-15) 12 (7-15) — — —”
New coal-mine-development considerations in financing
Pederson, J. A., Gleason, W. S., & Colegate, J. C. (1982) · OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information)
Multiresistente gramnegative Erreger
Kern, J. M. (2021) · Springer Reference Medizin · doi:10.1007/978-3-642-54676-1_548-2
(2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw456
Waele, J. J. D., Lipman, J., Akova, M., Bassetti, M., Dimopoulos, G., Kaukonen, M., Koulenti, D., Martin, C., Montravers, P., Rello, J., et al. (2015) · Intensive Care Medicine · doi:10.1007/s00134-015-3772-7
Self-citationCalandra, T., & Guery, B. P. (2018) · Springer eBooks · doi:10.1007/978-3-319-73506-1_12
Imani, S., Buscher, H., Day, R. O., Gentili, S., Jones, G. R. D., Marriott, D., Norris, R. L. G., & Sandaradura, I. (2021) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-021-04291-6
Starl, A., Hiort, B., Kehmann, J., Kim, S. H., Hofmann, M., & Hopf, H. (2022) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-022-00927-3
“5, 6, 7 und 8) wie bereits in der Literatur beschrieben [8, 25].”
BackgroundShahbazi, F., Shojaei, L., Farvadi, F., & Kadivarian, S. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2093713
(2017) · Nihon Kyukyu Igakukai Zasshi Journal of Japanese Association for Acute Medicine · doi:10.1002/jja2.12182
Shi, Q., Huang, C., Chen, W., Wu, S., Ji, J., Ying, C., Wu, H., & Xiao, Y. (2022) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2022.106334
Clinical Management of Endotoxemia: Antibiotics
Cutuli, S. L., Gennenzi, V., Vargas, J., & PASCALE, G. D. (2023) · Springer eBooks · doi:10.1007/978-3-031-18591-5_6
Roberts, J. A. (2022) · Journal of Pharmacy Practice and Research · doi:10.1002/jppr.1851
Self-citationAvoiding pitfalls in antibiotic therapy: the antibiotic stewardship approach
Huppertz-Thyssen, M., & Saavedra, C. R. (2022) · Magna Scientia UCEVA · doi:10.54502/msuceva.v2n2a1
Antimicrobials in the Management of Sepsis
Jacobi, J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88271-2.00032-8
Lowman, W. (2023) · Southern African Journal of Infectious Diseases · doi:10.4102/sajid.v38i1.498
“2,10 Thus, a reliable marker of a wild-type isolate with MICs within the ECOFF range is a clinically useful tool to guide both antimicrobial choice and dose.”
MethodAntiinfektive Therapie in der Intensivmedizin
Sakka, S. G. (2023) · Intensivmedizin up2date · doi:10.1055/a-2078-3265
Antiinfektive Therapie in der Intensivmedizin
Sakka, S. G. (2023) · Krankenhaushygiene up2date · doi:10.1055/a-2167-1487
Жукова, О. В., Sudakov, V. A., Vorobyeva, O. A., Chesnokova, N. N., & Shimanovsky, N. L. (2024) · Pharmaceutical Chemistry Journal · doi:10.1007/s11094-024-03067-4
Metadata
- Authors
- Roberts, J. A., Paul, S. K., Akova, M., Bassetti, M., De Waele, J. J., Dimopoulos, G., Kaukonen, K.-M., Koulenti, D., Martin, C., Montravers, P., Rello, J., Rhodes, A., Starr, T., Wallis, S. C., Lipman, J., Study, D., Roberts, J. A., Lipman, J., Starr, T., Wallis, S. C., Paul, S. K., Margarit Ribas, A., De Waele, J. J., De Crop, L., Spapen, H., Wauters, J., Dugernier, T., Jorens, P., Dapper, I., De Backer, D., Taccone, F. S., Rello, J., Ruano, L., Afonso, E., Alvarez-Lerma, F., Gracia-Arnillas, M. P., Fernandez, F., Feijoo, N., Bardolet, N., Rovira, A., Garro, P., Colon, D., Castillo, C., Fernado, J., Lopez, M. J., Fernandez, J. L., Arribas, A. M., Teja, J. L., Ots, E., Carlos Montejo, J., Catalan, M., Prieto, I., Gonzalo, G., Galvan, B., Blasco, M. A., Meyer, E., Del Nogal, F., Vidaur, L., Sebastian, R., Garde, P. M., Martin Velasco, M. D. M., Zaragoza Crespo, R., Esperatti, M., Torres, A., Montravers, P., Baldesi, O., Dupont, H., Mahjoub, Y., Lasocki, S., Constantin, J. M., Payen, J. F., Martin, C., Albanese, J., Malledant, Y., Pottecher, J., Lefrant, J.-Y., Jaber, S., Joannes-Boyau, O., Orban, C., Ostermann, M., McKenzie, C., Berry, W., Smith, J., Lei, K., Rubulotta, F., Gordon, A., Brett, S., Stotz, M., Templeton, M., Rhodes, A., Ebm, C., Moran, C., Kaukonen, K.-M., Pettila, V., Dimopoulos, G., Koulenti, D., Xristodoulou, A., Theodorou, V., Kouliatsis, G., Sertaridou, E., Anthopoulos, G., Choutas, G., Rantis, T., Karatzas, S., Balla, M., Papanikolaou, M., Myrianthefs, P., Gavala, A., Fildisis, G., Koutsoukou, A., Kyriakopoulou, M., Petrochilou, K., Kompoti, M., Michalia, M., Clouva-Molyvdas, F.-M., Gkiokas, G., Nikolakopoulos, F., Psychogiou, V., Malliotakis, P., Akoumianaki, E., Lilitsis, E., Koulouras, V., Nakos, G., Kalogirou, M., Komnos, A., Zafeiridis, T., Chaintoutis, C., Arvaniti, K., Matamis, D., Chaintoutis, C., Kydona, C., Gritsi-Gerogianni, N., Giasnetsova, T., Giannakou, M., Soultati, I., Chytas, I., Antoniadou, E., Antipa, E., Lathyris, D., Koukoubani, T., Paraforou, T., Spiropoulou, K., Bekos, V., Spring, A., Kalatzi, T., Nikolaou, H., Laskou, M., Strouvalis, I., Aloizos, S., Kapogiannis, S., Soldatou, O., Bassetti, M., Adembri, C., Villa, G., Giarratano, A., Maurizio Raineri, S., Cortegiani, A., Montalto, F., Strano, M. T., Ranieri, V. M., Sandroni, C., De Pascale, G., Molin, A., Pelosi, P., Montagnani, L., Urbino, R., Mastromauro, I., De Rosa, F. G., Ranieri, V. M., Cardoso, T., Afonso, S., Goncalves-Pereira, J., Baptista, J. P., Akova, M., & Ozveren, A.
- Affiliations
- Universitat Autònoma de Barcelona (ES)
- The University of Queensland (AU)
- Ghent University Hospital (BE)
- Centre Hospitalier Universitaire de Nîmes (FR)
- University General Hospital Attikon (GR)
- Sorbonne Paris Cité (FR)
- St George's, University of London (GB)
- University of Palermo (IT)
- University of Genoa (IT)
- Hacettepe University (TR)
- ORCID
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-01-14
- Volume
- 58
- Issue
- 8
- Pages
- 1072-1083
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2101416655
- Cited by
- 1,090
- References
- 31
- Citations by year
- 2026: 75 · 2025: 98 · 2024: 83 · 2023: 125 · 2022: 115 · 2021: 125 · 2020: 86 · 2019: 84 · 2018: 69 · 2017: 71 · 2016: 66 · 2015: 57 · 2014: 34
- FWCI
- 55.40
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- HAL (submittedVersion)
- Institutional Research Information System (University of Udine) (submittedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Florence Research (University of Florence) (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Hacettepe University Institutional Repository (hacettepe.edu.tr) (submittedVersion, other-oa)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Funders
- National Institute for Health and Care Research (NIHR/CS/009/007)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Keywords
- beta-lactam antibiotics, antibiotic dosing, critically ill patients, intensive care unit, pharmacokinetics, pharmacodynamics, free drug concentration, time above MIC, patient outcomes
- MeSH terms
- Aged, Anti-Bacterial Agents, Bacterial Infections, Blood Chemical Analysis, Female, Humans, Intensive Care Units, International Cooperation, Male, Microbial Sensitivity Tests, Middle Aged, Prospective Studies, Models, Statistical, Critical Illness, Treatment Outcome, beta-Lactams
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.